Eiger BioPharmaceuticals to Participate in Three Upcoming Investor Conferences
Citi's 17th Annual
- Date:
Thursday, September 8, 2022 - Location:
Boston, MA - Format: One-on-one meetings
H.C. Wainwright 24th Annual
- Date & Time:
Monday, September 12, 2022 at2:00 p.m. ET - Location:
New York, NY - Format: Company presentation and one-on-one meetings
- Date & Time:
Wednesday, September 14, 2022 at3:45 p.m. ET - Location:
New York, NY - Format: Company presentation and one-on-one meetings
A live webcast of each presentation will be available on the Investors section of the
Eiger is a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus (HDV) and other serious diseases. The Eiger HDV platform includes two first-in-class therapies in Phase 3 that target critical host processes involved in viral replication. All five Eiger rare disease programs have been granted FDA Breakthrough Therapy designation: lonafarnib and peginterferon lambda for HDV, Zokinvy for progeria, and avexitide for both congenital hyperinsulinism and post-bariatric hypoglycemia.
For additional information about Eiger and its clinical programs, please visit www.eigerbio.com.
Contacts
Investors:
[email protected]
Media:
SVP, Corporate Affairs
[email protected]
View original content to download multimedia:https://www.prnewswire.com/news-releases/eiger-biopharmaceuticals-to-participate-in-three-upcoming-investor-conferences-301616160.html
SOURCE